Pilot Study Evaluate Efficacy of Grazoprevir + Elbasvir for 12 or 16 Weeks in Liver Transplant Recipients.
Status:
Withdrawn
Trial end date:
2017-12-01
Target enrollment:
Participant gender:
Summary
Pilot, single center, open-label study to evaluate the efficacy and tolerability of
Grazoprevir and Elbasvir in HCV GT1 and 4 liver transplant recipients.30 liver transplant
recipients with hepatitis C recurrence.